Framework for the acceptability of technological health innovations [25]. 著者: Wezzie S. Lora (18139765)

主題:

Comparative matrix: summary of Ag-RDT acceptability across countries. 著者: Wezzie S. Lora (18139765)

主題:

Attributes of interviews (N = 228). 著者: Wezzie S. Lora (18139765)

主題:

Signal strength of ADE at the drug level ranked by reports. 著者: Jun Hua Lai (22676523)

主題:

Outcomes distribution of drug patients with the top 50 positive signal frequency by 4 methods (ROR PRR IC MGPS). 著者: Jun Hua Lai (22676523)

主題:

Time-to-onset analysis using the Weibull distribution test. 著者: Jun Hua Lai (22676523)

主題:

Characteristics of AEs reports. 著者: Jun Hua Lai (22676523)

主題:

Top 50 drugs sorted by frequency of positive signals stratified by reporter – by 4 methods (ROR PRR IC MGPS). 著者: Jun Hua Lai (22676523)

主題:

Gender Difference analysis of the top 50 drugs ranked by frequency by four methods (ROR PRR IC MGPS). 著者: Jun Hua Lai (22676523)

主題:

Top 50 Drugs with positive signals by frequency – by four methods (ROR PRR IC MGPS). 著者: Jun Hua Lai (22676523)

主題:

Two-by-two contingency table for disproportionality analysis. 著者: Jun Hua Lai (22676523)

主題:

The top 50 drugs by frequency of positive signals stratified by sex – by 4 methods (ROR PRR IC MGPS). 著者: Jun Hua Lai (22676523)

主題:

Flowchart. 著者: Jun Hua Lai (22676523)

主題:

The top 25 drugs sorted by frequency of positive signals stratified by age – by 4 methods (ROR PRR IC MGPS). 著者: Jun Hua Lai (22676523)

主題:

The principles of disproportionate measurement and the criteria for signal detection. 著者: Jun Hua Lai (22676523)

主題: